

IN THE SPECIFICATION

Please amend the third paragraph at page 21 to the first paragraph on page 22, as follows:

Generation of antigen-specific CTL. The generation of OVA-specific CTL has been described previously (11). In brief, spleen cells were obtained from mice primed 1-2 weeks earlier by i.p. injection of 5×10^6 EG.7 cells. Isolated spleen cells (3×10^6) were incubated with irradiated EG.7 cells (20,000 rad; 10^6 cells) for five days (in the presence or absence of cytokines or antibodies-see below). Effector cells used in the *in vitro* CTL assay (see below) were collected from these cultures and recognized the OVA₂₅₇₋₂₆₄ (SIINFKEL, SEQ ID NO: 1) peptide in the context of H-2K^b (15). To study the effect of MIF neutralization *in vivo*, EG7-primed mice received an injection of anti-MIF mAb or control IgG (0.5 mg, i.p.) On the day of tumor cell implantation and then daily for 1 week. Spleen cells from anti-MIF or control IgG treated mice then were isolated and assessed for CTL activity *in vitro* as described below.